BioPharma Resources

Drug Trial Radar · NCT06409130

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Effects of NNC0194-0499 Alone and in Combination With Semaglutide, of Semaglutide Alone, and of Cagrilintide Alone and in Combination With Semaglutide on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

270

Actual

Start

May 20, 2024

Primary completion

Nov 21, 2025

Study completion Jan 12, 2026

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
May 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.

Conditions

  • Alcohol-related Liver Disease

Interventions

  • NNC0194-0499Drug

    Administered subcutaneously.

  • SemaglutideDrug

    Administered subcutaneously.

  • NNC0194-0499 placeboDrug

    Administered subcutaneously.

  • Semaglutide placebo (Group A)Drug

    Administered subcutaneously.

  • Cagrilintide + semaglutideDrug

    Administered subcutaneously.

  • CagrilintideDrug

    Administered subcutaneously.

  • Cagrilintide placeboDrug

    Administered subcutaneously.

  • Semaglutide placebo (Group B)Drug

    Administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Enhanced Liver Fibrosis (ELF)Time frame: From week 0 to week 28

Locations

102 sites in 14 countries. Site status is shown where the registry gives one.

  • The Institute for Liver Health

    Chandler, Arizona

  • Arizona Liver Center

    Tucson, Arizona

  • Del Sol Research Management, LLC

    Tucson, Arizona

  • OM Research LLC

    Lancaster, California

  • California Liver Research Institute

    Pasadena, California

  • Covenant Metabolic Specialists LLC

    Fort Myers, Florida

  • Miguel Rebollar PA

    Hialeah, Florida

  • UF Hlth Jacksonville

    Jacksonville, Florida

  • Univ of Miami/Schiff Ctr

    Miami, Florida

  • Covenant Metabolic Specialists LLC

    University Park, Florida

  • Rush University Med. Cntr

    Chicago, Illinois

  • Kansas Medical Clinic, PA

    Topeka, Kansas

  • Louisiana Research Center, LLC

    Shreveport, Louisiana

  • Boston Medical Center_Cary

    Boston, Massachusetts

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Jubilee Clinical Research, Inc.

    Las Vegas, Nevada

  • DSI Research,LLC

    Springboro, Ohio

  • Univ of Pennsylvania Hospital

    Philadelphia, Pennsylvania

  • UPMC_Center for Liver Care

    Pittsburgh, Pennsylvania

  • Digestive Health Research, TN

    Hermitage, Tennessee

  • Texas Clinical Research Institute

    Arlington, Texas

  • The Liver Institute

    Dallas, Texas

  • South Texas Research Institute

    Edinburg, Texas

  • Baylor St. Luke's Medical Center

    Houston, Texas

  • Houston Research Institute

    Houston, Texas

  • Amer. Rrsch Corp-TX Liver Inst

    San Antonio, Texas

  • Pinnacle Clinical Research

    San Antonio, Texas

  • Liver Specialists of Texas

    Sugar Land, Texas

  • Velocity Clinical Res, Waco

    Waco, Texas

  • Momentum Clinical Research Darlinghurst

    Darlinghurst, New South Wales, Australia

  • Nepean Hospital

    Kingswood, New South Wales, Australia

  • St George Hospital

    Kogarah, New South Wales, Australia

  • Westmead Hospital - Storr Liver Centre

    Westmead, New South Wales, Australia

  • Eastern Clinical Research Unit Box Hill

    Box Hill, Victoria, Australia

  • St Vincent's Hospital Melbourne - Gastroenterology Department

    Fitzroy, Victoria, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • Fiona Stanley Hospital - Hepatology

    Murdoch, Western Australia, Australia

  • MHAT St. Ivan Rilski Gorna Oriahovitsa EOOD

    Gorna Oryahovitsa, Bulgaria

  • Acibadem City Clinic UMHAT Tokuda EAD, Gastroenterology

    Sofia, Bulgaria

  • UMHAT Aleksandrovska EAD, Clinic of Endocrinology and Metabolic Diseases

    Sofia, Bulgaria

Showing 40 of 102 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.